Intranasal replicon SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmission
Madeleine F. Jennewein, Michael D. Schultz, Samuel Beaver, Peter Battisti, Julie Bakken, Derek Hanson, Jobaida Akther, Fen Zhou, Raodoh Mohamath, Jasneet Singh, Noah Cross, Darshan N. Kasal, Matthew Ykema, Sierra Reed, Davies Kalange, Isabella R. Cheatwood, Jennifer L. Tipper, Jeremy B. Foote, R. Glenn King, Aarón Silva-Sánchez, Kevin S. Harrod, Davide Botta, Alana Gerhardt, Corey Casper, Troy D. Randall, Frances E. Lund, Emily A. Voigt
Topics & Concepts
RepliconVirologyTransmission (telecommunications)ImmunityNasal administrationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Respiratory systemMedicine2019-20 coronavirus outbreakImmunologyViral sheddingBiologyVirusImmune systemPlasmidInfectious disease (medical specialty)DiseaseInternal medicineGeneBiochemistryOutbreakElectrical engineeringEngineeringSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyRespiratory viral infections research